HistoSonics is developing a non-invasive therapy that uses histotripsy, a therapeutic focused ultrasound energy, to destroy tumors.
HistoSonics reaches $2.25B valuation after investor-led majority acquisition
To date, HistoSonics said its Edison system has treated more than 2,000 patients at over 50 leading U.S. medical centers.
HistoSonics Edison system gains early market access in the U.K.
The Edison system provides a non-invasive, robotic treatment for liver tumors, according to HistoSonics.
Robotics investments recap: April 2019
Despite a few high-profile failures, robotics investments kept going strong in April 2019, with funding flowing to companies working on self-driving cars, supply chain automation, and robots in healthcare.
HistoSonics raises $54M for medical robotics platform
HistoSonics closed a $54 million Series C round for its robotically-assisted platform it says uses sound energy to liquify and destroy cancerous tumors without affecting surrounding tissue. Branded as Robotically Assisted Sonic Therapy (RAST), the histotripsy technology combines robotics, imaging and sensor technology to exploit microscopic air bubbles that naturally exist in tissue. HistoSonics’ Series…